Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233222 | 0.90 | CYP3A4 (0.35) | CYP3A4ALOX15KDM4ETDP2ABCB1 | |
| SCHEMBL16586412 | 0.89 | MAPT (0.36) | CYP3A4ALOX15PTGER4ALDH1A1MAPT | |
| SCHEMBL20568239 | 0.89 | PDE4B (0.43) | KDM4ETDP2PDE4BPTGER4ALDH1A1 | |
| SCHEMBL2177649 | 0.87 | KMT2A (0.34) | CYP3A4ALOX15KDM4EPTGER4ALDH1A1 | |
| SCHEMBL16110105 | 0.83 | TDP2 (0.33) | ALOX15KDM4ETDP2PDE4BALDH1A1 | |
| SCHEMBL16472183 | 0.82 | EGLN2 (0.37) | CYP3A4TDP2ABCC9CXCR2 | |
| SCHEMBL2178893 | 0.81 | ABCB1 (0.34) | ABCB1 | |
| SCHEMBL19513344 | 0.81 | CXCR2 (0.45) | CYP3A4ALDH1A1MAPTCXCR2 | |
| SCHEMBL30881186 | 0.81 | CXCR2 (0.45) | CYP3A4ALDH1A1MAPTCXCR2 | |
| SCHEMBL12383682 | 0.78 | CYP3A4 (0.34) | CYP3A4KDM4EALDH1A1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207701-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207701-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011022337-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011022337-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207701-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | CYP3A4 3967/4885ALOX15 3432/4885KDM4E 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.